A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs Fasinumab (Primary)
  • Indications Back pain; Pain
  • Focus Registrational; Therapeutic Use
  • Acronyms FACT CLBP 1
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 17 Aug 2018 Planned End Date changed from 2 Apr 2019 to 1 May 2019.
    • 17 Aug 2018 Planned primary completion date changed from 21 Aug 2018 to 22 Aug 2018.
    • 29 Jun 2018 This trial has been discontinued in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top